Cancer Treatment and Research During the COVID-19 Pandemic: Experience of the First 6 Months

Begoña de las Heras; Kamal S. Saini; Frances Boyle; Felipe Ades; Evandro de Azambuja; Ivana Bozovic-Spasojevic; Marco Romano; Marta Capelan; Rajeev Prasad; Pugazhenthi Pattu; Christophe Massard; Chia Portera; Monika Lamba Saini; Brajendra Prasad Singh; Ramachandran Venkitaraman; Richard McNally; Manuela Leone; Enrique Grande; Sudeep Gupta

doi:10.1007/s40487-020-00124-2

Cancer Treatment and Research During the COVID-19 Pandemic: Experience of the First 6 Months

Begoña de las Heras, Kamal S. Saini, Frances Boyle, Felipe Ades, Evandro de Azambuja, Ivana Bozovic-Spasojevic, Marco Romano, Marta Capelan, Rajeev Prasad, Pugazhenthi Pattu, Christophe Massard, Chia Portera, Monika Lamba Saini, Brajendra Prasad Singh, Ramachandran Venkitaraman, Richard McNally, Manuela Leone, Enrique Grande, Sudeep Gupta

Résultats de recherche: Contribution à un journal › !!Comment/debate

1 Citation (Scopus)

Résumé

The coronavirus disease-2019 (COVID-19) pandemic has had a significant impact on patients with underlying malignancy. In this article, we summarize emerging data related to patients with cancer and COVID-19. Among patients with COVID-19, a higher proportion have an underlying diagnosis of cancer than seen in the general population. Also, patients with malignancy are likely to be more vulnerable than the general population to contracting COVID-19. Mortality is significantly higher in patients with both cancer and COVID-19 compared with the overall COVID-19-positive population. The early months of the pandemic saw a decrease in cancer screening and diagnosis, as well as postponement of standard treatments, which could lead to excess deaths from cancer in the future.

langue originale	Anglais
Pages (de - à)	171-182
Nombre de pages	12
journal	Oncology and Therapy
Volume	8
Numéro de publication	2
Les DOIs	https://doi.org/10.1007/s40487-020-00124-2
état	Publié - 1 déc. 2020

Accès au document

10.1007/s40487-020-00124-2

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

de las Heras, B., Saini, K. S., Boyle, F., Ades, F., de Azambuja, E., Bozovic-Spasojevic, I., Romano, M., Capelan, M., Prasad, R., Pattu, P., Massard, C., Portera, C., Saini, M. L., Singh, B. P., Venkitaraman, R., McNally, R., Leone, M., Grande, E., & Gupta, S. (2020). Cancer Treatment and Research During the COVID-19 Pandemic: Experience of the First 6 Months. Oncology and Therapy, 8(2), 171-182. https://doi.org/10.1007/s40487-020-00124-2

@article{8d904665a5bb4cbca637aa2b77e07f8c,

title = "Cancer Treatment and Research During the COVID-19 Pandemic: Experience of the First 6 Months",

abstract = "The coronavirus disease-2019 (COVID-19) pandemic has had a significant impact on patients with underlying malignancy. In this article, we summarize emerging data related to patients with cancer and COVID-19. Among patients with COVID-19, a higher proportion have an underlying diagnosis of cancer than seen in the general population. Also, patients with malignancy are likely to be more vulnerable than the general population to contracting COVID-19. Mortality is significantly higher in patients with both cancer and COVID-19 compared with the overall COVID-19-positive population. The early months of the pandemic saw a decrease in cancer screening and diagnosis, as well as postponement of standard treatments, which could lead to excess deaths from cancer in the future.",

keywords = "COVID-19, Cancer, Coronavirus, Immuno-oncology, Malignancy, Mortality, Pandemic, Risk, SARS-CoV-2, Therapy",

author = "{de las Heras}, Bego{\~n}a and Saini, {Kamal S.} and Frances Boyle and Felipe Ades and {de Azambuja}, Evandro and Ivana Bozovic-Spasojevic and Marco Romano and Marta Capelan and Rajeev Prasad and Pugazhenthi Pattu and Christophe Massard and Chia Portera and Saini, {Monika Lamba} and Singh, {Brajendra Prasad} and Ramachandran Venkitaraman and Richard McNally and Manuela Leone and Enrique Grande and Sudeep Gupta",

note = "Publisher Copyright: {\textcopyright} 2020, The Author(s).",

year = "2020",

month = dec,

day = "1",

doi = "10.1007/s40487-020-00124-2",

language = "English",

volume = "8",

pages = "171--182",

journal = "Oncology and Therapy",

issn = "2366-1070",

number = "2",

}

de las Heras, B, Saini, KS, Boyle, F, Ades, F, de Azambuja, E, Bozovic-Spasojevic, I, Romano, M, Capelan, M, Prasad, R, Pattu, P, Massard, C, Portera, C, Saini, ML, Singh, BP, Venkitaraman, R, McNally, R, Leone, M, Grande, E & Gupta, S 2020, 'Cancer Treatment and Research During the COVID-19 Pandemic: Experience of the First 6 Months', Oncology and Therapy, VOL. 8, Numéro 2, p. 171-182. https://doi.org/10.1007/s40487-020-00124-2

TY - JOUR

T1 - Cancer Treatment and Research During the COVID-19 Pandemic

T2 - Experience of the First 6 Months

AU - de las Heras, Begoña

AU - Saini, Kamal S.

AU - Boyle, Frances

AU - Ades, Felipe

AU - de Azambuja, Evandro

AU - Bozovic-Spasojevic, Ivana

AU - Romano, Marco

AU - Capelan, Marta

AU - Prasad, Rajeev

AU - Pattu, Pugazhenthi

AU - Massard, Christophe

AU - Portera, Chia

AU - Saini, Monika Lamba

AU - Singh, Brajendra Prasad

AU - Venkitaraman, Ramachandran

AU - McNally, Richard

AU - Leone, Manuela

AU - Grande, Enrique

AU - Gupta, Sudeep

PY - 2020/12/1

Y1 - 2020/12/1

N2 - The coronavirus disease-2019 (COVID-19) pandemic has had a significant impact on patients with underlying malignancy. In this article, we summarize emerging data related to patients with cancer and COVID-19. Among patients with COVID-19, a higher proportion have an underlying diagnosis of cancer than seen in the general population. Also, patients with malignancy are likely to be more vulnerable than the general population to contracting COVID-19. Mortality is significantly higher in patients with both cancer and COVID-19 compared with the overall COVID-19-positive population. The early months of the pandemic saw a decrease in cancer screening and diagnosis, as well as postponement of standard treatments, which could lead to excess deaths from cancer in the future.

AB - The coronavirus disease-2019 (COVID-19) pandemic has had a significant impact on patients with underlying malignancy. In this article, we summarize emerging data related to patients with cancer and COVID-19. Among patients with COVID-19, a higher proportion have an underlying diagnosis of cancer than seen in the general population. Also, patients with malignancy are likely to be more vulnerable than the general population to contracting COVID-19. Mortality is significantly higher in patients with both cancer and COVID-19 compared with the overall COVID-19-positive population. The early months of the pandemic saw a decrease in cancer screening and diagnosis, as well as postponement of standard treatments, which could lead to excess deaths from cancer in the future.

KW - COVID-19

KW - Cancer

KW - Coronavirus

KW - Immuno-oncology

KW - Malignancy

KW - Mortality

KW - Pandemic

KW - Risk

KW - SARS-CoV-2

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=105002959639&partnerID=8YFLogxK

U2 - 10.1007/s40487-020-00124-2

DO - 10.1007/s40487-020-00124-2

M3 - Comment/debate

AN - SCOPUS:105002959639

SN - 2366-1070

VL - 8

SP - 171

EP - 182

JO - Oncology and Therapy

JF - Oncology and Therapy

IS - 2

ER -